Premium
Delineation of erythropoiesis in normal and malignant bone marrow using monoclonal antibody AS‐E1 directed against transferrin receptors (CD71)
Author(s) -
Olesen Gitte,
Carlsen Ingrid,
Skovbo Anni,
Hokland Marianne,
Hokland Peter
Publication year - 1998
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1998.tb00996.x
Subject(s) - transferrin receptor , immunocytochemistry , erythropoiesis , bone marrow , monoclonal antibody , myeloid , biology , microbiology and biotechnology , antigen , transferrin , antibody , cell sorting , pathology , immunology , flow cytometry , medicine , endocrinology , anemia
We have delineated the erythropoietic compartment in normal and malignant bone marrow (BM) by using the monoclonal antibody (mAb) AS‐E1 directed against the transferrin receptor by flow cytometric (FCM) analysis. In normal BM we found a bimodal expression in antigen density with a minor subset (˜3%) expressing AS‐E1 high and a larger subset (˜15%) expressing AS‐E1 low . By fluorescence activated cell sorting, morphological examination of smears stained by immunocytochemistry and by BFU–E assays the AS‐E1 high fraction was shown to contain cells of erythroid origin (proerythroblasts, basophilic erythroblasts and polychromatic erythroblasts), whereas the AS‐E1 low fraction consisted mainly of promyelocytes and myelocytes. In patients with malignant hematological disorders we found a more pronounced heterogeneity in the density and the degree of AS‐E1 low expression compared to normal BM, and to further characterize the AS‐E1 low cells in patients and to exclude that this broad reactivity interfered with the identification of the AS‐E1 high cells, we employed triple‐color FCM assays with mAbs directed against the myeloid surface markers CD13 and CD66 in addition to AS‐E1. In all patients we found that 80–90% of the AS‐E1 low cells co‐expressed CD13 and/or CD66 and thus were of myeloid origin. Finally, we evaluated 2 methods for determination of the AS‐E1 high subset and found an assay involving forward light scatter and logAS‐E1 density to be sufficient. We conclude that AS‐E1 high is a valid FCM marker for the normal erythropoiesis.